Literature DB >> 20493947

C601S mutation in the androgen receptor results in partial loss of androgen function.

Rajender Singh1, Pooja Singh, Nalini J Gupta, Baidyanath Chakrabarty, Lalji Singh, Kumarasamy Thangaraj.   

Abstract

The present study was undertaken on a case of partial androgen insensitivity syndrome to look at the etiology of the disorder. The patient exhibited a female phenotype despite 46,XY chromosome complement. Direct DNA sequencing of coding region of the androgen receptor gene in this case revealed a 2329G>C substitution (cDNA sequence reference) in exon 3 of the gene. The substitution resulted in replacement of Cys with Ser at codon 601 of the ligand-binding domain of the protein. Analyses on 200 control samples revealed absence of this substitution(s). In vitro assays were done using COS-1 cells. The mutation resulted in partial (∼40%) loss of ligand-binding and significant (∼70%) loss of downstream transactivation function. The mutation was absent in the controls. The findings are particularly interesting since another substitution at the same codon (TGC-TTC) has been reported in association with complete androgen insensitivity syndrome.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493947     DOI: 10.1016/j.jsbmb.2010.05.006

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  2 in total

1.  Effects of androgen receptor mutation on testicular histopathology of patient having complete androgen insensitivity.

Authors:  Ihtisham Bukhari; Guangyuan Li; Liu Wang; Furhan Iqbal; Huan Zhang; Jiansheng Zhu; Hui Liu; Xiangdong Fang; Nasser M Al-Daghri; Howard J Cooke; Yuanwei Zhang; Xiaohua Jiang
Journal:  J Mol Histol       Date:  2017-03-15       Impact factor: 2.611

2.  Mutational Analysis of Androgen Receptor Gene in Two Families with Androgen Insensitivity.

Authors:  Radha Ramadevi Akella
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.